Terminated PHASE3 INTERVENTIONAL 2-arm NCT00120289

Niacin Plus Statin to Prevent Vascular Events

AIM HIGH: Niacin Plus Statin to Prevent Vascular Events

Sponsor: Abbott

Conditions Atherosclerosis Cardiovascular Diseases Cerebrovascular Accident Coronary Disease Heart Diseases Myocardial Infarction

Interventions Extended release niacin Simvastatin

Updated 11 times since 2017 Last updated: Mar 8, 2016 Started: Sep 30, 2005 Primary completion: Sep 30, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.

Other terminated trials from Abbott

See all terminations from Abbott

Other Atherosclerosis trials with similar outcome

NCT03606642 · Phase PHASE2 · Aug 2022

Browse all Atherosclerosis trials

A PHASE3 clinical study on Atherosclerosis and Cardiovascular Diseases, this trial is terminated or withdrawn. The trial is conducted by Abbott and has accumulated 11 data snapshots since 2005. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 6 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Axio Research. LLC
National Heart, Lung, and Blood Institute (NHLBI)

Data source: Axio Research. LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Baltimore, United States , Birmingham, United States , Bloomfield Hills, United States , Buffalo, United States , Burbank, United States , Calgary, Canada , Cambridge, Canada , Charlottesville, United States and 66 more locations